Research Article
Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma
Table 3
The relationship between the signature and clinical features.
| id | Age | Gender | Grade | Stage | T | M | N |
| MMP9 | 0.005 (0.996) | 0.569 (0.571) | 5.384 (2.875-07) | −1.611 (0.110) | −1.966 (0.051) | −1.098 (0.319) | −0.592 (0.555) | RBP7 | −0.7 (0.485) | 1.125 (0.268) | 2.232 (0.027) | −2.055 (0.042) | −1.859 (0.066) | −1.316 (0.245) | −1.611 (0.114) | PDGFRA | −0.422 (0.674) | 0.778 (0.442) | 3.048 (0.004) | −3.046 (0.003) | −3.008 (0.003) | −0.481 (0.647) | −1.242 (0.218) | AHNAK | −0.899 (0.370) | 1.378 (0.176) | 5.605 (7.957-07) | −3.667 (3.488-04) | −3.898 (1.461-04) | 0.926 (0.389) | −2.267 (0.026) | OAS1 | 2.082 (0.039) | −2.634 (0.010) | −2.181 (0.045) | 2.19 (0.032) | 2.18 (0.032) | 2.913 (0.023) | 1.74 (0.085) | OLR1 | 0.702 (0.484) | −0.098 (0.922) | 1.415 (0.170) | −1.059 (0.292) | −1.021 (0.309) | 2.971 (0.005) | −0.393 (0.695) | RAC3 | −0.491 (0.624) | 0.868 (0.390) | 2.724 (0.009) | −0.472 (0.638) | 0.142 (0.887) | −1.139 (0.306) | −1.763 (0.083) | SLIT2 | −0.968 (0.335) | 1.006 (0.320) | 3.448 (0.001) | −3.546 (5.295-04) | −3.545 (5.237-04) | −1.724 (0.144) | −1.937 (0.057) | IGF1 | 0.152 (0.879) | 0.776 (0.442) | 2.909 (0.004) | −3.54 (5.794-04) | −3.087 (0.003) | −0.981 (0.365) | −1.126 (0.264) | AGTR1 | −1.482 (0.141) | 0.54 (0.592) | −0.795 (0.439) | 0.37 (0.712) | 0.427 (0.670) | 0.032 (0.976) | 0.719 (0.473) | riskScore | −0.297 (0.767) | 2.126 (0.041) | 2.479 (0.019) | −2.683 (0.008) | −2.595 (0.010) | −0.931 (0.394) | −1.806 (0.075) |
|
|